J&J’s Tremfya superior to Stelara in Phase II/III Crohn’s disease trial
Tremfya was superior to both Stelara and placebo in all endoscopic endpoints in the Phase III portion of the Galaxi programme.
Tremfya was superior to both Stelara and placebo in all endoscopic endpoints in the Phase III portion of the Galaxi programme.
Heartbeam AI plus VCG outperformed an expert panel of three cardiologists by 40% in detecting atrial flutter.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
UK clinical trials industry tackles recent changes in the sector
AstraZeneca’s Phase III Covid-19 antibody trial meets primary endpoints
Allucent receives grant for decentralised Covid-19 vaccine trial
NeuroSense taps PhaseV’s ML tech for Phase III ALS trial analysis